Related Experiment Video
Updated: Jul 10, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer
1Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium. eric.vancutsem@uz.kuleuven.ac.be
Abstract:
The monoclonal antibodies against the epidermal growth factor receptor (EGFR) are active in patients with metastatic colorectal cancer (CRC; mCRC). This activity has been shown initially in irinotecan- and chemotherapy-refractory mCRC. The correlation of rash after EGFR inhibitors and activity has led to the concept of the dose until rash study. Clinical trials evaluating this concept are ongoing. However, many unresolved challenges remain regarding this question. New challenges include the development of the most optimal schedule of the EGFR inhibitors and the evaluation of their role in less advanced stages and in the preoperative treatment of liver metastases of CRC.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Clinical Applications of Epidermal Stem Cells
